Patrick Forde
@patrickforde.bsky.social
Immunotherapy believer. Lung Cancer & Mesothelioma. 🇮🇪 🇺🇸
https://scholar.google.com/citations?hl=en&user=tWgfWfoAAAAJ
https://scholar.google.com/citations?hl=en&user=tWgfWfoAAAAJ
Glad to be here and thanks for invite @tnewsomdavis.bsky.social great meeting and discussion so far!
March 3, 2025 at 1:26 PM
Glad to be here and thanks for invite @tnewsomdavis.bsky.social great meeting and discussion so far!
Seems to be specifically PD1 pathway blockade resistance so some use CTLA4-PD1 combinations (in advanced nsclc)
November 18, 2024 at 10:45 PM
Seems to be specifically PD1 pathway blockade resistance so some use CTLA4-PD1 combinations (in advanced nsclc)
I would guess it’s a reaction to the drop in US cancer trial accrual post covid & conversely the FDA wanting a minimum percent US accrual to phase 3s but some bright ideas may be best left unexplored
November 18, 2024 at 10:38 PM
I would guess it’s a reaction to the drop in US cancer trial accrual post covid & conversely the FDA wanting a minimum percent US accrual to phase 3s but some bright ideas may be best left unexplored